NASDAQ:LMDX LumiraDx (LMDX) Stock Forecast, Price & News $0.20 -0.01 (-5.16%) (As of 12:04 PM ET) Add Compare Share Share Today's Range$0.20▼$0.2150-Day Range$0.22▼$0.4652-Week Range$0.20▼$1.61Volume365,347 shsAverage Volume315,961 shsMarket Capitalization$64.98 millionP/E RatioN/ADividend YieldN/APrice Target$1.45 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media LumiraDx MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside625.0% Upside$1.45 Price TargetShort InterestHealthy0.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector638th out of 976 stocksPharmaceutical Preparations Industry295th out of 451 stocks 3.3 Analyst's Opinion Consensus RatingLumiraDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.45, LumiraDx has a forecasted upside of 625.0% from its current price of $0.20.Amount of Analyst CoverageLumiraDx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.32% of the float of LumiraDx has been sold short.Short Interest Ratio / Days to CoverLumiraDx has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LumiraDx has recently increased by 19.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLumiraDx does not currently pay a dividend.Dividend GrowthLumiraDx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LMDX. Previous Next 2.3 News and Social Media Coverage News SentimentLumiraDx has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for LumiraDx this week, compared to 1 article on an average week.Search Interest1 people have searched for LMDX on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LumiraDx insiders have not sold or bought any company stock.Percentage Held by Insiders35.41% of the stock of LumiraDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.59% of the stock of LumiraDx is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LumiraDx are expected to grow in the coming year, from ($0.51) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LumiraDx is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LumiraDx is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About LumiraDx (NASDAQ:LMDX) StockLumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.Read More LMDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LMDX Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comLumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSeptember 21, 2023 | finance.yahoo.comWhat Makes LumiraDx Limited (LMDX) a New Buy StockOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 27, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on LumiraDx (LMDX)August 27, 2023 | finance.yahoo.comEarnings Update: LumiraDx Limited (NASDAQ:LMDX) Just Reported And Analysts Are Trimming Their ForecastsAugust 25, 2023 | finance.yahoo.comLumiraDx Limited (NASDAQ:LMDX) Q2 2023 Earnings Call TranscriptAugust 24, 2023 | finance.yahoo.comLumiraDx Reports Second Quarter 2023 ResultsAugust 24, 2023 | finance.yahoo.comLumiraDx Limited (LMDX) Reports Q2 Loss, Misses Revenue EstimatesOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 21, 2023 | finance.yahoo.comThis LumiraDx Insider Increased Their Holding By 150% Last YearAugust 16, 2023 | finance.yahoo.comLumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24August 1, 2023 | benzinga.comCapitalGainsReport Potential Breakouts Watchlist (SHGI, IQST, PHUN LMDX)August 1, 2023 | finance.yahoo.comPositive Sentiment Still Eludes LumiraDx Limited (NASDAQ:LMDX) Following 27% Share Price SlumpJune 30, 2023 | markets.businessinsider.comLumiraDx Submits Medical Device Application To FDA For COVID Ultra TestJune 30, 2023 | finance.yahoo.comLumiraDx Submits First 510(k) Application to the FDA for COVID Ultra TestJune 21, 2023 | benzinga.comLumiraDx shares are trading higher after the company received UK approval for its COVID Ultra and COVID & RSV Tests.June 21, 2023 | msn.comLumiraDX Skyrockets on Bagging Approval for COVID-19 and RSV Tests in the U.K.June 21, 2023 | investorplace.comWhy Is LumiraDx (LMDX) Stock Up 30% Today?June 20, 2023 | finance.yahoo.comLumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV TestsJune 6, 2023 | ca.finance.yahoo.comLMDX - LumiraDx LimitedMay 18, 2023 | msn.comLadenburg Thalmann Maintains LumiraDx (LMDX) Buy RecommendationMay 18, 2023 | msn.comGoldman Sachs Maintains LumiraDx (LMDX) Neutral RecommendationMay 17, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for LumiraDxMay 17, 2023 | msn.comRaymond James Maintains LumiraDx (LMDX) Outperform RecommendationMay 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LumiraDx (LMDX) and Aerovate Therapeutics (AVTE)May 16, 2023 | msn.comLumiraDx: Q1 Earnings InsightsMay 16, 2023 | finance.yahoo.comLumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue EstimatesSee More Headlines Receive LMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter. Email Address LMDX Company Calendar Last Earnings8/24/2023Today10/03/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LMDX CUSIPN/A CIK1685428 Webwww.lumiradx.com Phone354-640-0540FaxN/AEmployees1,210Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.45 High Stock Price Forecast$2.70 Low Stock Price Forecast$0.80 Forecasted Upside/Downside+570.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-447,790,000.00 Net Margins-268.45% Pretax Margin-264.58% Return on EquityN/A Return on Assets-77.95% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.01 Sales & Book Value Annual Sales$254.48 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / Book-0.66Miscellaneous Outstanding Shares318,550,000Free Float205,749,000Market Cap$68.93 million OptionableNot Optionable Beta1.13 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Ron Zwanziger (Age 69)Co-Founder, Chairman & CEO Dr. David Scott Ph.D. (Age 66)Co-Founder, CTO & Director Dr. Jerome F. McAleer Ph.D. (Age 67)Co-Founder, Chief Scientist & Director Mr. Dorian LeBlanc CPA (Age 48)CFO & VP of Global Operations Ms. Veronique Ameye Esq. (Age 46)M.B.A., Deputy CEO & Gen. Counsel Ms. Colleen McMillenVP of CommunicationsAndy WardNational Sales Director - UKMr. David Walton DMS (Age 69)Chief Commercial Officer Giffin DaughtridgePres of North America Commercial Operations & Global Molecular SolutionsMore ExecutivesKey CompetitorsVaccinexNASDAQ:VCNXCytomX TherapeuticsNASDAQ:CTMXOcuphire PharmaNASDAQ:OCUPIO BiotechNASDAQ:IOBTNkartaNASDAQ:NKTXView All CompetitorsInstitutional OwnershipColony Group LLCBought 26,070 shares on 8/15/2023Ownership: 0.042%Two Sigma Securities LLCBought 67,635 shares on 8/14/2023Ownership: 0.025%Bank of Montreal CanBought 120,000 shares on 8/2/2023Ownership: 0.038%Beacon Investment Advisory Services Inc.Bought 174,730 shares on 7/21/2023Ownership: 0.191%View All Institutional Transactions LMDX Stock - Frequently Asked Questions Should I buy or sell LumiraDx stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LMDX shares. View LMDX analyst ratings or view top-rated stocks. What is LumiraDx's stock price forecast for 2023? 2 analysts have issued 12-month price objectives for LumiraDx's shares. Their LMDX share price forecasts range from $0.80 to $2.70. On average, they anticipate the company's share price to reach $1.45 in the next year. This suggests a possible upside of 570.1% from the stock's current price. View analysts price targets for LMDX or view top-rated stocks among Wall Street analysts. How have LMDX shares performed in 2023? LumiraDx's stock was trading at $0.90 at the start of the year. Since then, LMDX stock has decreased by 76.0% and is now trading at $0.2164. View the best growth stocks for 2023 here. Are investors shorting LumiraDx? LumiraDx saw a increase in short interest in September. As of September 15th, there was short interest totaling 334,100 shares, an increase of 19.5% from the August 31st total of 279,500 shares. Based on an average daily volume of 147,200 shares, the short-interest ratio is currently 2.3 days. Approximately 0.3% of the company's shares are short sold. View LumiraDx's Short Interest. When is LumiraDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our LMDX earnings forecast. How were LumiraDx's earnings last quarter? LumiraDx Limited (NASDAQ:LMDX) released its quarterly earnings data on Thursday, August, 24th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01. The firm had revenue of $21 million for the quarter, compared to the consensus estimate of $21.07 million. During the same quarter in the prior year, the company posted ($0.58) earnings per share. What is LumiraDx's stock symbol? LumiraDx trades on the NASDAQ under the ticker symbol "LMDX." How do I buy shares of LumiraDx? Shares of LMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is LumiraDx's stock price today? One share of LMDX stock can currently be purchased for approximately $0.22. How much money does LumiraDx make? LumiraDx (NASDAQ:LMDX) has a market capitalization of $68.93 million and generates $254.48 million in revenue each year. The company earns $-447,790,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. How many employees does LumiraDx have? The company employs 1,210 workers across the globe. How can I contact LumiraDx? LumiraDx's mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The official website for the company is www.lumiradx.com. The company can be reached via phone at 354-640-0540 or via email at ir@lumiradx.com. This page (NASDAQ:LMDX) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LumiraDx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.